Sacral nerve stimulation versus intravesical botulinum toxin injections for medically refractory overactive bladder: A contemporary review of UK treatment from both clinician and patients’ perspectives

Abstract

Introduction:

In the UK, 10,000 refractory overactive bladder patients per year receive intravesical onabotulinum toxin A treatment and 300 receive sacral nerve stimulation implants. Current National Institute for Health and Care Excellence guidelines propose using onabotulinum toxin A before sacral nerve stimulation whilst the European Association of Urology (EAU) and American Urological Association (AUA) suggests both be offered with equipoise. The aim of this study was to ascertain both patients and clinician views regarding these two treatments.

Subjects/methods:

Fifty consecutive overactive bladder patients who were refractory to behavioural and medical therapy anonymously completed a structured questionnaire about their treatment preferences. Additionally, 100 UK consultant urologists anonymously completed a separate questionnaire about their treatment preferences and which treatment modalities they had available for use in their Trusts.

Results:

Of patients, 60% preferred sacral nerve stimulation over onabotulinum toxin A, of whom 80% would happily randomise into a trial between the two treatments. Ninety-seven per cent of 100 consultant urologists in the UK have access to onabotulinum toxin A in their hospitals, but only 39% have access to sacral nerve stimulation. Of clinicians given access to all available options, 71% would use onabotulinum toxin A as their first choice treatment for refractory overactive bladder.

Conclusion:

There appears to be a significant disparity between current UK overactive bladder guidance, National Health Service accessibility to onabotulinum toxin A and sacral nerve stimulation therapies, the views of clinicians, and patient preferences for treatment.

Level of evidence:

Keywords

Overactive bladder urinary incontinence healthcare resource utilisation health-related quality of life onabotulinum toxin sacral nerve stimulation

Get full access to this article

View all access options for this article.

References

Abrams

et al . The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Neurol Urodyn 2002; 21: 167–178.

Irwin

Milsom

Hunskaar

et al . This population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; 50: 1306–1314.

Reeves

Irwin

. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006; 50: 1050–1057.

Brown

McGhan

Chokroverty

. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6: S574–S579.

Irwin

Mungapen

Kopp

et al . The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2008; 103: 202.

Turner

Shaw

et al . The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK. BJU Int 2004; 93: 1246–1252.

McGhan

.Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am J Manag Care 2001; 7: S62–S75.

Shaw

Das Gupta

Bushnell

. The extent and severity of urinary incontinence amongst women in UK GP waiting rooms. Fam Pract 2006; 25: 497–506.

Lloyd

Crawford

McSkimming

et al . The impact of age, gender, and severity of overactive bladder wet on quality of life, productivity, treatment patterns and satisfaction. J Clin Urol 2017; 10: 512–522.

10.

NHS Digital. Hospital episode statistics, admitted patient care – England 2014–15, http://content.digital.nhs.uk/catalogue/PUB19124/hosp-epis-stat-admi-trea-spec-2014–15-tab.xlsx (2015, accessed 3 November 2016).

11.

Brazzelli

Murray

et al . Efficacy and safety if sacral nerve stimulation for urinary urge incontinence: A systematic review. J Urol 2006; 175: 835–841.

12.

Schmidt

Jonas

et al . Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol 1999; 162: 352–357.

13.

Weil

Ruiz-Cerda

et al . Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: A prospective randomized clinical trial. Eur Urol 2000; 37: 161–171.

14.

Hassouna

Siegel

et al . Sacral neuromodulation in the treatment of urgency-frequency symptoms: A multicenter study on efficacy and safety. J Urol 2000; 163: 1849–1854.

15.

Brazzelli

Murray

Fraser

et al . Systematic review of the efficacy and safety of sacral nerve stimulation for urinary urge incontinence and urgency- frequency. Aberdeen: Review Body for Interventional Procedures; 2003. Commissioned by the National Institute for Clinical Excellence, http://almacen-gpc.dynalias.org/publico/Stimulacion%20sacra.pdf (accessed 16 May 2014).

16.

Mangera

Apostolidis

Andersson

et al . An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 2014; 65: 981–990.

17.

Cui

Wang

Liu

et al . Botulinum toxin-A injections for idiopathic overactive bladder: A systematic review and meta-analysis. Urol Int 2013; 91: 429–438.

18.

Duthie

Vincent

Herbison

et al . Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011; 12: CD005493.

19.

Anger

Weinberg

Suttorp

et al . Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: A systematic review of the literature. J Urol 2010; 183: 2258–2264.

20.

Chapple

et al . OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial. Eur Urol 2013; 64: 249–256.

21.

Nitti

Dmochowski

Herschorn

et al . OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial. J Urol 2013; 189: 2186–2193.

22.

Tincello

Kenyon

Abrams

et al . Botulinum toxin A versus placebo for refractory detrusor overactivity in women: A randomised blinded placebo-controlled trial of 240 women (the RELAX Study). Eur Urol 2012; 62: 515–517.

23.

Denys

Le Normand

Ghout

et al . Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: A multicentre, double-blind, randomised, placebo- controlled dose-ranging study. Eur Urol 2012; 61: 520–529.

24.

Dmochowski

Chapple

Nitti

et al . Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: A double- blind, placebo controlled, randomized, dose ranging trial. J Urol 2010; 184: 2416–2422.

25.

Sahai

Dowson

Khan

et al . Repeated injections of botulinum toxin- A for idiopathic detrusor overactivity. Urology 2010; 75: 552–558.

26.

Amundsen

et al . The refractory overactive bladder: Sacral neuromodulation vs. botulinum toxin assessment: ROSETTA trial. Contemp Clin Trials 2014; 37: 272–283.

27.

Amundsen

Richter

Menefee

et al . OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women. A randomized clinical trial. JAMA 2016; 316: 1366–1374.

28.

National Institute for Health and Care Excellence. Online Clinical Guideline (CG171): Urinary Incontinence in Women. Sept 2013. https://www.nice.org.uk/guidance/cg171 (accessed 3 December 2015).

29.

https://www.nice.org.uk/guidance/cg97 (accessed 3 December 2015).

30.

American Urological Association – Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults: AUA/SUFU Guideline. 2012. http://www.auanet.org/guidelines/overactive-bladder-(oab)-(aua/sufu-guideline-2012-amended-2014)#x2939 (accessed 3 December 2015).

31.

http://uroweb.org/wp-content/uploads/20-Urinary-Incontinence_LR.pdf

32.

Freemantle

Khalaf

Loveman

et al . OnabotulinumtoxinA in the treatment of overactive bladder: A cost-effectiveness analysis versus best supportive care in England and Wales. Eur J Health Econ 2016; 17: 911–921.

33.

Autiero

Hallas

Betts

et al . The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. BJU Int 2015; 116: 945–954.

34.

Leong

de Wachter

Joore

et al . Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int 2011; 108: 558–564.

35.

NHS England Commissioning Policy: Sacral Nerve Stimulation for Overactive Bladder. July 2015. https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/10/e10pb-sacrl-nrve-stimltn-bladdr.pdf (accessed 3 December 2015).

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.12 MB